Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the benefit of OMS103HP for Injection (OMS103HP) compared with vehicle irrigation solution for prevention of pain and pain relief in subjects undergoing meniscectomy. The pain relief is assessed based on Visual Analog Scale (VAS) Pain Scores in the immediate 24-hour postoperative period and for seven days postoperatively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy

NCT01406561

Meniscal Tear

COMPLETED PHASE3

Post-operative Efficacy and Safety Study

NCT00904085

Post-operative Pain

COMPLETED PHASE3

Periarticular Injection and Hamstring Block Versus Placebo for Pain Control in Anterior Cruciate Ligament Reconstruction

NCT05248724

Anterior Cruciate Ligament Reconstruction

COMPLETED NA

The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty

NCT01191593

Postoperative Pain Knee Arthroplasty

COMPLETED PHASE4

Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

NCT04246541

Meniscus Tear, Tibial Pain, Postoperative Postoperative Complications +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug

Group Type EXPERIMENTAL

OMS103HP

Intervention Type DRUG

Maximum 6 bags of OMS103HP irrigation solution

Vehicle

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type DRUG

Maximum of 6 bags of vehicle irrigation solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OMS103HP

Maximum 6 bags of OMS103HP irrigation solution

Intervention Type DRUG

Vehicle

Maximum of 6 bags of vehicle irrigation solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has voluntarily signed informed consent form, including HIPAA Authorization.
2. Subject is ≥ 18 and ≤ 75 years of age.
3. Subject is in good general health with a traumatic or degenerative meniscal cartilage injury (full tear) that occurred at least 14 days prior to the day of arthroscopic surgery.
4. Subject is undergoing unilateral meniscectomy.
5. Subject's physical examination is within normal limits or examination is clinically nonsignificant as determined by the Investigator, and subject is in good general health.
6. Subject's laboratory evaluations are within normal limits or evaluations are clinically nonsignificant as determined by the Investigator.
7. Subject, if female and of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) agrees to use an effective method of birth control for the duration of her study involvement.
8. Subject is at minimal risk from anesthesia and is classified according to the American Society of Anesthesiologists Physical Status Classification as either PS-1 (a normal healthy patient) or PS-2 (a patient with mild systemic disease that results in no functional limitation). See Appendix VI.

Exclusion Criteria

10. Subject is able to be proficient in the use of the ePRO device (documented at the site).

1. Subject with significant arthritis (\>2 on the Kellgren-Lawrence Scale).
2. Subject with a history of reactive synovial disease.
3. Subject with current, or history of, complex regional pain syndrome (Type I, i.e., reflex sympathetic dystrophy, or Type II, i.e., causalgia), chronic pain, attendance at a chronic pain clinic, or neurologic disorder associated with any sensory deficit of the lower extremities.
4. Subject with current, or history of fibromyalgia.
5. Subject taking ANY ANALGESIC (including salicylates, opioids, propoxyphene, etc.) on the day of surgery from 12:00 A.M. until after the procedure, except for medications authorized by the Investigator or delegated staff.
6. Subject taking any of the following medications within the stated time frames prior to the day of surgery.

1. Amitriptyline within 30 days
2. More than two doses of sumatriptan, (or any other drug in the triptan class), ondansetron, or other prescription serotonergic or histaminic drug within 14 days
3. More than two doses of any oral, parenteral, or intravenous steroids (e.g., dexamethasone for antiemetic prophylaxis) within 3 months
4. More than two doses of oxymetazoline or other nasal decongestant/cold/cough/allergy medication (including loratadine) within 7 days
5. More than two doses of ketoprofen or other NSAID (including COX-2 inhibitors) within 7 days (except for piroxicam, as indicated below)
6. Subject who has taken more than two doses of opioid pain medication within the prior seven days of surgery or chronic use of opioid pain medications for greater than 6 weeks within the prior year
7. More than two doses of piroxicam within 14 days
8. Subject with a history of intra-articular corticosteroid injection in the operative knee within the two months prior to the meniscectomy
7. Subject expected to undergo any of the following procedures concurrent with meniscectomy:

1. Arthroscopic patellar tendon debridement
2. Patellar alignment
3. Lateral or retinacular release
4. Excision synovectomy (minor synovectomy to improve arthroscopic visualization is acceptable)
5. Concurrent ligamentous procedure
6. Microfracture
7. Abrasion arthroplasty
8. Chondral transplantation
9. Use of more than three portals
8. Subject with allergies to any of the individual ingredients in OMS103HP, to related compounds (e.g., other NSAIDs or tricyclic antidepressants), or to opioid analgesics.
9. Subject who is pregnant or breast-feeding.
10. Subject with Worker's Compensation claim(s) under dispute or mediation.
11. Subject with history of drug or alcohol abuse.
12. Subject who has taken or used an investigational drug or device within 30 days prior to the day of surgery.
13. Subject with a history or presence of systemic disease (renal, hepatic, psychiatric, etc.), which in the opinion of the Medical Monitor and the Principal Investigator, may place the subject's health at risk by participation in the study.
14. Subject who is expected to receive a regional block for analgesia for this procedure.
15. Subject who is considered by the Investigator for any reason to be an unsuitable candidate for receipt of an investigational drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No